Triple-negative breast cancer (TNBC) is a breast cancer subtype that tests negative for estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptors 2 (HER2). Since TNBC tumors lack known targets for drug development, the treatment options have been mostly limited to chemotherapy.
Recently, however, new treatment options have become available, including immunotherapy, PARP inhibitors and the antibody drug conjugate Trodelvy (sacituzumab govitecan). Additionally, there are other types of drugs and regimens currently being studied in clinical trials, including drugs targeting the PI3K/AKT/mTOR pathway, the androgen receptor pathway, and regimens that combine PARP inhibitors, immune checkpoint inhibitors and other types of drugs.
See below for information on current treatment options and drugs currently being studied in clinical trials.
Overview of Approved and Investigational Drugs for TNBC
- 2020 EMBRACE Metastatic Breast Cancer Virtual Forum Series | Research Update for Triple-Negative MBC Webinar by Dana-Farber Cancer Institute
- Medical Update: Triple-Negative Metastatic Breast Cancer Webinar by Living Beyond Breast Cancer
- Recently Approved and Emerging Therapies for Triple-Negative Breast Cancer by The ASCO Post
- Immunotherapy, ADCs, PARP Inhibitors Make Waves in Metastatic TNBC by OncLive
Clinical Trials for People with Metastatic TNBC
- Metastatic Trial Search: Clinical Trials for TNBC
- Metastatic Trial Search: Clinical Trials studying immunotherapy for TNBC
- Metastatic Trial Search: Clinical Trials studying targeted therapies for TNBC
Last Modified on March 22, 2021